Rosemarijn H. Ettema
Amsterdam UMC Location VUmc, University Medical Center Utrecht, University of Amsterdam
Papers
5
Total Citations
85
H-Index
4
About
Rosemarijn H. Ettema is a leading researcher in the field of urologic oncology, with a primary focus on advancing the use of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) for the management of prostate cancer. Her work has fundamentally reshaped how clinicians stage and treat this disease, particularly in high-risk and recurrent settings. Ettema’s major contributions include demonstrating that PSMA PET/CT is associated with improved oncological outcomes in men receiving salvage radiation therapy for biochemical recurrence—a finding with over 30 citations that has influenced clinical guidelines. She has also clarified the prognostic value of PSMA-based lymph node staging, showing that molecular imaging (miN1) status can stratify outcomes in node-positive patients, and has rigorously assessed the accuracy and reproducibility of PSMA PET/CT for local tumor staging. Her development of a novel nomogram to predict salvage therapy outcomes further exemplifies her commitment to personalized medicine. With a growing body of highly cited work, Ettema is a pivotal figure in translating advanced molecular imaging into tangible survival benefits for prostate cancer patients.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5